These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29570560)

  • 1. Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection.
    Yakoot M; El-Shabrawi MH; AbdElgawad MM; Mahfouz AA; Helmy S; Abdo AM; El-Khayat HR
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):86-89. PubMed ID: 29570560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
    Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
    EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.
    Abdel Ghaffar TY; El Naghi S; Abdel Gawad M; Helmy S; Abdel Ghaffar A; Yousef M; Moafy M
    J Viral Hepat; 2019 Feb; 26(2):263-270. PubMed ID: 30380158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
    Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
    Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Cheng PN; Chiu YC; Chien SC; Chiu HC
    J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.
    Mandorfer M; Schwabl P; Steiner S; Scheiner B; Chromy D; Bucsics T; Stättermayer AF; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    AIDS; 2016 Apr; 30(7):1039-47. PubMed ID: 26760453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Sarwar S; Tarique S; Aleem A; Khan AA
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1035-1039. PubMed ID: 31274596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
    Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
    Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y
    Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
    Liu CH; Chen YS; Wang SS; Liu CJ; Su TH; Yang HC; Hong CM; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2018 Jan; 66(2):289-292. PubMed ID: 29020359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    Ridruejo E; Cheinquer H; Marciano S; Mendizabal M; Piñero F; Wolff FH; de Araujo A; Coelho Borges S; Kliemann D; Fleck A; de Maman Í; Nader LA; Garrastazul P; Bermúdez C; Haddad L; Gadano A; Silva M
    J Viral Hepat; 2019 Oct; 26(10):1200-1209. PubMed ID: 31141239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
    Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
    Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
    J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.